Unknown

Dataset Information

0

Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.


ABSTRACT: Respiratory syncytial virus (RSV) causes lower respiratory tract infections and bronchiolitis, mainly affecting children under 2 years of age and immunocompromised patients. Currently, there are no available vaccines or efficient pharmacological treatments against RSV. In recent years, tremendous efforts have been directed to understand the pathological mechanisms of the disease and generate a vaccine against RSV. Although RSV is highly infectious, not all the patients who get infected develop bronchiolitis and severe disease. Through various sequencing studies, single nucleotide polymorphisms (SNPs) have been discovered in diverse receptors, cytokines, and transcriptional regulators with crucial role in the activation of the innate immune response, which is implicated in the susceptibility to develop or protect from severe forms of the infection. In this review, we highlighted how variations in the key genes affect the development of innate immune response against RSV. This data would provide crucial information about the mechanisms of viral infection, and in the future, could help in generation of new strategies for vaccine development or generation of the pharmacological treatments.

SUBMITTER: Cordova-Davalos LE 

PROVIDER: S-EPMC9462631 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of genetic polymorphisms related to innate immune response on respiratory syncytial virus infection in children.

Córdova-Dávalos Laura Elena LE   Hernández-Mercado Alicia A   Barrón-García Claudia Berenice CB   Rojas-Martínez Augusto A   Jiménez Mariela M   Salinas Eva E   Cervantes-García Daniel D  

Virus genes 20220909 6


Respiratory syncytial virus (RSV) causes lower respiratory tract infections and bronchiolitis, mainly affecting children under 2 years of age and immunocompromised patients. Currently, there are no available vaccines or efficient pharmacological treatments against RSV. In recent years, tremendous efforts have been directed to understand the pathological mechanisms of the disease and generate a vaccine against RSV. Although RSV is highly infectious, not all the patients who get infected develop b  ...[more]

Similar Datasets

| S-EPMC5621907 | biostudies-literature
| S-EPMC4814860 | biostudies-other
| S-EPMC4752219 | biostudies-literature
| S-EPMC5116403 | biostudies-literature
| S-EPMC4829966 | biostudies-literature
| S-EPMC8249238 | biostudies-literature
2016-05-09 | GSE77087 | GEO
| S-EPMC2919413 | biostudies-literature
| S-EPMC6819090 | biostudies-literature
| S-EPMC5587315 | biostudies-literature